Myriad Genetics Inc. has announced the successful closing of a new $200 million credit facility with OrbiMed, a prominent global healthcare investment firm. This five-year senior secured term loan includes $125 million of funded capital, with an option for Myriad to borrow an additional $75 million until June 30, 2027. The facility, which matures on July 31, 2030, bears interest based on the one-month secured overnight financing rate $(SOFR)$ plus 6.50% annually, with a SOFR floor of 2.50%. The credit facility is secured by nearly all of Myriad's assets and replaces the company's previous asset-based lending facility. Evercore acted as the exclusive financial advisor for the transaction. This funding will support Myriad's growth strategy and objectives in the field of molecular diagnostic testing and precision medicine.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。